FRANKFURT – Swiss drugmaker Novartis said two late-stage trials showed its drug secukinumab improved symptoms of psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.
The trials, which involved a total of more than 1,000 people, showed the drug improved peripheral joint disease and prevented joint damage compared with a placebo and helped clear patients’ skin, Novartis said in a statement on Thursday.
[eap_ad_2]
It plans to file for regulatory approval of secukinumab to treat psoriatic arthritis around the world next year.
It expects to receive approval of the drug to treat moderate-to-severe plaque psoriasis later this year or early next year. It is also testing the drug for the treatment of ankylosing spondylitis (AS) and rheumatoid arthritis (RA). (Reuters)
[eap_ad_3]
